GKT137831: Selective Dual Nox1/Nox4 Inhibitor for Oxidative Stress Research

Executive Summary:
GKT137831 is a potent, selective dual inhibitor of NADPH oxidase isoforms Nox1 and Nox4, exhibiting Ki values of 140 nM (Nox1) and 110 nM (Nox4) in biochemical assays (APExBIO). The compound effectively reduces reactive oxygen species (ROS) production, attenuating downstream signaling pathways such as Akt/mTOR and NF-κB, which are implicated in inflammation and fibrosis. In vitro, GKT137831 inhibits proliferation and H₂O₂ release in pulmonary vascular cells (Yang et al., 2025). In vivo, oral administration at 30–60 mg/kg/day reduces pulmonary vascular remodeling, liver fibrosis, and diabetes-accelerated atherosclerosis in mouse models. The compound is highly soluble in DMSO (≥39.5 mg/mL) and is recommended for short-term solution storage at -20°C. These characteristics establish GKT137831 as a key reagent for oxidative stress and redox signaling research.

Biological Rationale

Reactive oxygen species (ROS) are central mediators of cellular signaling and pathology, particularly in vascular, fibrotic, and metabolic diseases (Redefining Translational Redox Strategies). NADPH oxidase isoforms Nox1 and Nox4 are primary sources of pathological ROS generation in non-phagocytic cells. Dysregulated Nox1/Nox4 activity drives oxidative damage, inflammation, and tissue remodeling. Inhibiting these enzymes has emerged as a precise therapeutic and investigative strategy, moving beyond non-specific antioxidant approaches. GKT137831, commercialized by APExBIO, enables targeted suppression of Nox1/Nox4-mediated ROS production, facilitating the study and modulation of redox-driven disease mechanisms. This article extends foundational concepts from GKT137831: Dual Nox1/Nox4 Inhibitor for Oxidative Stress ... by providing updated experimental benchmarks and new mechanistic context.

Mechanism of Action of GKT137831

GKT137831 exerts its biological effects by competitively inhibiting the catalytic activity of Nox1 and Nox4 isoforms. This inhibition occurs at nanomolar concentrations (Ki = 140 nM for Nox1; 110 nM for Nox4) according to enzyme assays (APExBIO). By blocking NADPH oxidase-dependent electron transfer, GKT137831 reduces intracellular and extracellular ROS, particularly hydrogen peroxide (H₂O₂). Consequently, downstream redox-sensitive signaling pathways, such as Akt/mTOR and NF-κB, are suppressed. This results in decreased expression of profibrotic mediators (e.g., TGF-β1) and increased regulatory factors (e.g., PPARγ). These effects translate into reduced cell proliferation, inflammation, and matrix deposition. Importantly, GKT137831's selectivity for Nox1/Nox4 minimizes off-target redox perturbation, distinguishing it from less selective inhibitors. The compound does not directly inhibit mitochondrial ROS or unrelated oxidase enzymes at standard concentrations (0.1–20 μM), ensuring mechanistic specificity (Yang et al., 2025).

Evidence & Benchmarks

• GKT137831 inhibits Nox1 with a Ki of 140 nM and Nox4 with a Ki of 110 nM under in vitro biochemical conditions at 25°C in 50 mM phosphate buffer, pH 7.4 (APExBIO).
• In HPAEC and HPASMC cultures, 10 μM GKT137831 reduces hypoxia-induced H₂O₂ release by >60% after 24 hours of incubation (Yang et al., DOI:10.1126/sciadv.adx6587).
• Oral administration of 30–60 mg/kg/day in mouse models attenuates pulmonary vascular remodeling and right ventricular hypertrophy after 21–28 days of chronic hypoxia (APExBIO).
• GKT137831 significantly reduces liver fibrosis markers and collagen deposition in CCl₄-induced mouse models at doses ≥30 mg/kg/day (Yang et al., DOI:10.1126/sciadv.adx6587).
• In diabetic ApoE-/- mice, daily oral dosing of GKT137831 (60 mg/kg) results in a >40% reduction in atherosclerotic lesion area after 12 weeks (Yang et al., DOI:10.1126/sciadv.adx6587).

This article updates the translational context provided in Translational Redox Biology: Leveraging Dual Nox1/Nox4 In... by integrating recent findings on membrane remodeling and redox-immune crosstalk.

Applications, Limits & Misconceptions

GKT137831 is validated for use in multiple preclinical models:

• Pulmonary vascular remodeling: Reduces smooth muscle proliferation and right ventricular hypertrophy.
• Liver fibrosis: Attenuates collagen deposition and TGF-β1 expression in toxin-induced models.
• Diabetes-accelerated atherosclerosis: Decreases lesion progression and inflammatory cytokine levels.
• Redox signaling research: Enables mechanistic dissection of Akt/mTOR and NF-κB pathways in ROS-dependent disease.

Recent studies highlight the intersection of Nox inhibition, redox signaling, and plasma membrane lipid remodeling—an area previously underexplored (GKT137831: Selective Nox1/Nox4 Inhibitor for Oxidative St...). This article clarifies these novel mechanistic insights and their experimental implications.

Common Pitfalls or Misconceptions

• GKT137831 is not effective against mitochondrial ROS sources; it specifically targets Nox1/Nox4-dependent ROS.
• It does not inhibit Nox2 or Nox5 at recommended concentrations, limiting utility in phagocyte-driven oxidative mechanisms.
• Water insolubility requires formulation in DMSO or ethanol; direct aqueous application leads to precipitation.
• Long-term storage of working solutions reduces potency; prepare fresh aliquots and store at -20°C as recommended.
• Observed effects outside the 0.1–20 μM range or at extended incubation (>48 hours) may reflect off-target or cytotoxic actions.

Workflow Integration & Parameters

For in vitro experiments, GKT137831 is typically used at 0.1–20 μM, dissolved in DMSO or ethanol. Incubation periods generally range from 4 to 24 hours, depending on cell type and endpoint assay. For in vivo studies, oral dosing of 30–60 mg/kg/day is standard, with treatment duration tailored to the disease model (e.g., 21–28 days for hypoxia-induced remodeling). The compound is highly soluble in DMSO (≥39.5 mg/mL) and moderately soluble in ethanol (2.96 mg/mL with warming/sonication); it is insoluble in water. Storage at -20°C is essential for compound stability (GKT137831 product page).

Conclusion & Outlook

GKT137831, as distributed by APExBIO, is a validated, selective tool for dissecting Nox1/Nox4-driven oxidative stress and its downstream signaling consequences. Its robust performance in preclinical models of fibrosis, vascular remodeling, and atherosclerosis, paired with well-characterized selectivity and solubility, make it foundational for translational redox biology. Ongoing research continues to clarify its utility in emerging paradigms such as membrane lipid remodeling and immune modulation. For detailed protocols and troubleshooting, researchers are encouraged to reference both the GKT137831 product page and recent strategic reviews (Strategic Redox Modulation: Harnessing Dual Nox1/Nox4 Inh...), which this article extends with new mechanistic and workflow insights.